The author discusses pT1 bladder cancer and the decision making involved and mentions the non-muscle-invasive bladder cancer in which the urologists need to consider progression and possible recurrence. He also talks about the neutrophil-to-lymphocyte ratio (NLR) which is now considered as a useful prognostic factor in cancers and change in NLR after the chemotherapy session.